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Obesity may be associated with increased risk of prostate cancer (PCa). According to one hypothesis, obesity could lower the risk of
non-aggressive tumours, while simultaneously increasing the risk of aggressive cancer. Furthermore, central adiposity may be
independently associated with PCa risk; it is also associated with diabetes, which itself may influence risk of PCa. We studied the
associations between height, body composition, and fat distribution, diabetes prevalence and risk of total, aggressive, and non-
aggressive PCa in 10564 initially cancer-free men (aged 45–73 years) of the population-based Malmo ¨ Diet and Cancer cohort.
Anthropometric and body composition measurements, including bioelectrical impedance for estimation of fat mass, were performed
by study nurses. Diabetes prevalence was self-reported. Cancer cases and clinical characteristics were ascertained through national
and regional registry data. Dietary and other background data were obtained through a modified diet history method and an
extensive questionnaire. During a mean follow-up of 11.0 years, 817 incidental PCa cases were diagnosed. Of these, 281 were
classified as aggressive. There were 202 cases occurring before 65 years of age. Height was positively associated with total and non-
aggressive PCa risk. Waist–hip ratio (WHR), a measure of central adiposity, was positively associated with PCa before age 65, and
less strongly, with total PCa. This association was independent of body mass index (BMI) and other potential confounders. General
adiposity, expressed as BMI or body fat percentage, and prevalent diabetes were not associated with PCa risk. In this study, WHR and
body height were stronger PCa predictors than general adiposity.
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Obesity has long been associated with increased risk of prostate
cancer (PCa), although studies have been inconsistent (MacInnis
and English, 2006). Risk has been suggested to differ according to
tumour grade: obesity lowering the risk of indolent, less aggressive
tumours, whereas increasing that of aggressive cancer (Freedland
et al, 2006), a view supported by a meta-analysis (MacInnis and
English, 2006), and, to some extent, by other work (Gong et al,
2006; Littman et al, 2007; Rodriguez et al, 2007; Wright et al, 2007).
Most studies have used body mass index (BMI) as a marker of
general obesity, but it has certain limitations, particularly in men,
because it does not differentiate muscle from fat mass (Willett,
1998). One solution might be to calculate fat mass and fat-free
mass from bioelectrical impedance (BIA) measurements
(Anonymous, 1996; MacInnis et al, 2003).
There is less support for the hypothesis that central adiposity
(measured as waist circumference or waist—hip ratio, WHR) is a
risk marker for PCa (MacInnis and English, 2006). Only a few
prospective studies have examined this association (Giovannucci
et al, 1997; Lee et al, 2001; MacInnis et al, 2003; Hubbard et al,
2004). Furthermore, central adiposity is a clinically established risk
factor for non-insulin dependent diabetes mellitus (NIDDM)
(Vazquez et al, 2007; Gastaldelli, 2008), and NIDDM has been
associated with lower risk of PCa (Bonovas et al, 2004), both low
grade and high grade (Gong et al, 2006). High insulin levels, as in
insulin resistance, which often precedes NIDDM, was recently
associated with lower risk of non-aggressive PCa (Stocks et al,
2007), although there was also a non-significant positive associa-
tion with aggressive cancer.
Tallness has also been associated with PCa risk (Engeland et al,
2003; MacInnis and English, 2006); perhaps reflecting an influence
of nutritional factors.
We investigated total, aggressive, and non-aggressive PCa in
relation to current obesity, body composition, height, and
prevalence of diabetes mellitus in a population-based cohort,
including a sub-cohort of younger men.
MATERIALS AND METHODS
The background population of the Malmo ¨ Diet and Cancer (MDC)
study, in Sweden’s third largest city (Berglund et al, 1993), consists
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who were living in Malmo ¨ during the screening period 1991–1996
(n¼74138). This population was identified through national
population registries, the final cohort consisting of 28098
individuals (participation rate 40.8%). Participants were recruited
through advertisements in local media and through invitation by
mail. The only exclusion criteria were inadequate Swedish
language skills and mental incapacity (Manjer et al, 2001, 2002);
the Ethics Committee at Lund University approved the design of
the MDC study (LU 51–90).
Waist circumference was measured midway between the lowest
rib margin and iliac crest; hip circumference horizontally at the
level of the greatest lateral extension of the hips. Bioelectrical
impedance was used for estimating body composition according to
manufacturer’s procedures (BIA 103, RJL-systems, Detroit, MI,
USA; single-frequency analyser). An algorithm (Sun et al, 2003)
was used to estimate body fat (BF) from impedance. The results
were highly correlated to results obtained by another algorithm,
developed in a similar population (Heitmann, 1990). Estimated BF
was used to calculate BF%.
A structured multiple-choice questionnaire was used in the
MDC study to collect information on sociodemographic factors,
smoking status, alcohol habits, health status, use of pharmaceutical
drugs, and several other factors. The agreement between baseline
questionnaire and its repeat after 3 weeks was high for most
variables (k values 40.75) (Manjer et al, 2002). The diabetes items
read: ‘Have you ever been treated for diabetes? Since what year?’
Persons who reported using oral anti-diabetic drugs were also
classified as diabetics.
The diet assessment, reported earlier (Wirfa ¨lt et al, 2002),
combines quantitative and semi-quantitative approaches to the
entire diet, including cooking methods (Callmer et al,1 9 9 3 ) .I t
consists of two parts: a ‘menu book’ for description of cooked meals
and registration of cold (including juices and alcoholic) beverages
and dietary supplements during seven consecutive days; and a 168-
item food questionnaire on regularly consumed foods during the
past year. Data on validity (Elmsta ˚hl et al,1 9 9 6 b ;R i b o l iet al,1 9 9 7 )
and reproducibility (Elmsta ˚hl et al, 1996a) have been reported.
Cancer cases were ascertained by record linkage with the
National Cancer Register. Cancer cases from the year 2005,
additional data on tumour stage and grade, pre-diagnostic serum
prostate-specific antigen (PSA) value, and reason for diagnosis
(symptoms, health examination, or other) were obtained from the
National Prostate Cancer Register (NPCR) (South Region). In the
South Region, to which Malmo ¨ belongs, registration was started in
1996 and is at least 95% complete. For cases diagnosed in 1991–
1995, the same data were manually extracted from medical records
using standard routines. The National Cancer Register is known to
be at least 98% complete. A validation of the NPCR data from
another region showed high validity for all variables, including one
used to classify non-aggressive and aggressive tumours (Sandblom
et al, 2003).
Of the 11063 men in the MDC cohort, 485 were already
diagnosed with cancer (excluding basal cell carcinomas) at study
entry, and were therefore excluded; 14 others were excluded
because of PCa diagnosis at autopsy, leaving 10564 men for
analysis. They were followed until date of death, date of PCa
diagnosis, or 31 December 2005, whichever came first. No
participants were lost to follow-up of vital status. Among them,
817 incident cases of PCa (‘total PCa’; ICD-9 code 185) occurred
between baseline examination and end of follow-up. The average
follow-up time in participants free of PCa at death (n¼1321) or at
the end of follow-up (n¼8426) was 11.0 years.
An aggressive case (‘aggressive Pca’) was defined as a tumour
with a clinical T stage of 3 or higher or tumour-positive lymph
nodes (N1) or one or more distant metastases (M1) or a Gleason
score of 8 or higher or a pre-treatment serum PSA value of at least
50ngml
 1 (Stocks et al, 2007); tumours were also classified as
aggressive (total 281) if the WHO grade was 3, and Gleason score
was unavailable (n¼6). In cases in which at least two of T stadium,
Gleason score, or PSA serum value were reported, and if none of
these factors indicated an aggressive tumour, the tumour was
classified as non-aggressive (n¼530). Staging data were unavail-
able or insufficient for 6 of the incident cases that with 530 cases of
non-aggressive cancers were excluded from analyses comparing
men with aggressive tumours with others. Details on stage and
grade have been reported earlier (Wallstro ¨m et al, 2007).
For PCa in younger people, we repeated all analyses in a sub-
cohort, the o65 sub-cohort, the end of follow-up being either at
date of death, date of PCa diagnosis, 31 December 2005, or the
man’s 65th birthday, whichever came first. This younger sub-
cohort consisted of 8194 men, among whom 202 incident PCa
cases (54 aggressive) occurred. Mean follow-up time for non-cases
was 7.7 years.
We examined the associations between total, aggressive, and
non-aggressive PCa incidence and height, waist circumference,
waist-hip ratio (WHR), BMI, BF%, and prevalence of diabetes. All
continuous variables were divided into quintile groups. The hazard
ratios (HR) of each distribution quintile (compared with the
lowest), and trends across the quintiles were assessed with Cox
proportional hazards regression with adjustment for age at
baseline. The time variable was number of days of follow-up after
baseline. Additionally, in a separate Cox analysis, BMI was divided
into pre-defined categories (World Health Organization, 2000)
with tests for overall differences between categories. We also
performed analyses of waist circumference and WHR with
adjustment for BMI, to assess risk associated with abdominal,
irrespective of general, adiposity. All analyses were age-adjusted
and were also performed in the o65 sub-cohort (202 cases). We
then repeated the above analyses with adjustment for a number of
potential confounders, selected from a survey of the current
scientific literature: co-habitation status, socioeconomic index,
alcohol habits, BF%, smoking history, birth country (Sweden/
other), total calcium intake, dietary intake of eicosapentaenoic acid
and docosahexaenoic acid, consumption of fruits, vegetables, and
red meat. The dietary variables were adjusted for total energy
intake (residual method) (Willett and Stampfer, 1998).
To further evaluate the consistency of our results, we repeated all
analyses (including subgroups) in three separate sessions. In the
first, we excluded asymptomatic cases (478 cases remaining in the
total group). In the second, we excluded persons not born in Sweden
(748 cases), and in the third, we excluded cases occurring within two
years of the beginning of follow-up (691 remaining cases).
RESULTS
Height was associated with increased risk of total PCa, although the
effect was limited to the highest quintile (range 182–203cm), and
was most evident among non-aggressive tumours (Table 1). No
other measures of body composition or fat distribution were
significantly associated with PCa risk, although being underweight
(BMI o18.5) was associated with higher risks than normal weight
across all PCa categories except the non-aggressive category; an
association with BMI-adjusted WHR was suggested. Neither
prevalent diabetes was significantly associated with PCa risk nor
height in the o65 sub-cohort (Table 2, age-adjusted analyses), there
was a weak, positive association with WHR. After adjustment for
BMI, the association was slightly stronger (HR per quintile 1.14,
95% CI 1.03–1.26). Similarly, waist circumference (adjusted for
BMI) was positively associated with risk in the o65 sub-cohort.
After adjustment for a number of possible confounders, the
increased risk of total PCa associated with greater height was
weakened (P for trend¼0.08, Table 3). However, the highest
quintile was still significantly different from the lowest (P¼0.018).
The associations between WHR and PCa, both in total and in the
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adjustment (Tables 2 and 3). The associations with being
underweight were also slightly stronger after adjustment (Table 2);
otherwise, the results were similar. Inspection of the data revealed
no suggestion of any significant interactions between any body
measure and aggressive vs non-aggressive tumours.
The association between high stature (tallest quintile) and
risk of total PCa was a robust finding in most models (exclusion
Table 1 Age-adjusted hazard ratios (with lower and upper limits of 95% confidence intervals) for measures of height, obesity, and diabetes prevalence and
total, aggressive, and non-aggressive cases of prostate cancer
a
Incident prostate cancer, entire cohort (n¼10564)
b
Non-cases
(n¼9747)
All cases (n¼817) Aggressive cases (n¼281) Non-aggressive cases (n¼530)
Median Range NN HR Lower Upper N HR Lower Upper N HR Lower Upper
Height (cm)
Quintile 1 168 p170 1798 144 1.00 50 1.00 93 1.00
Quintile 2 173 171–174 2011 182 1.20 0.97 1.49 71 1.40 0.97 2.01 109 1.10 0.84 1.46
Quintile 3 177 175–178 2263 182 1.11 0.89 1.38 65 1.20 0.83 1.74 115 1.06 0.81 1.39
Quintile 4 180 179–181 1536 116 1.09 0.85 1.39 36 1.06 0.69 1.63 80 1.12 0.83 1.51
Quintile 5 184 X182 2123 193 1.40 1.13 1.74 59 1.38 0.95 2.02 133 1.42 1.09 1.86
0.016 0.37 0.014
BMI
Underweight n/a p18.49 48 8 2.09 1.03 4.22 4 2.88 1.06 7.82 4 0.60 0.22 1.61
Normal n/a 18.50–24.99 3627 287 1.00 102 1.00 183 1.00
Overweight n/a 25.00–29.99 4803 417 1.04 0.90 1.21 140 0.97 0.75 1.25 274 0.65 0.24 1.75
Obese n/a X30.00 1253 105 1.04 0.84 1.30 35 0.95 0.65 1.40 69 0.65 0.24 1.78
Non-linear P 0.24
c 0.20
d 0.65
e
BMI
Quintile 1 22.2 p23.4 1949 158 1.00 61 1.00 96 1.00
Quintile 2 24.4 23.5–25.2 1957 164 0.97 0.78 1.20 53 0.80 0.55 1.15 110 1.07 0.82 1.41
Quintile 3 26.0 25.2–26.8 1928 168 0.98 0.79 1.22 59 0.87 0.61 1.25 107 1.04 0.79 1.38
Quintile 4 27.7 26.8–28.7 1940 175 1.03 0.83 1.28 57 0.85 0.59 1.22 117 1.15 0.88 1.51
Quintile 5 30.6 X28.7 1957 152 0.91 0.73 1.14 51 0.77 0.53 1.12 100 1.00 0.76 1.33
0.67 0.27 0.80
Body fat %
Quintile 1 15.7 p18.3 1952 146 1.00 53 1.00 93 1.00
Quintile 2 19.9 18.3–21.3 1915 184 1.23 0.99 1.52 72 1.33 0.93 1.89 108 1.14 0.86 1.50
Quintile 3 22.6 21.3–23.8 1941 157 1.04 0.83 1.31 54 0.99 0.68 1.44 102 1.06 0.80 1.41
Quintile 4 25.1 23.8–26.6 1933 166 1.07 0.86 1.33 46 0.81 0.55 1.21 120 1.22 0.93 1.60
Quintile 5 28.8 X26.6 1937 161 1.08 0.86 1.35 55 1.01 0.69 1.48 105 1.11 0.84 1.47
0.98 0.25 0.37
Waist (cm)
Quintile 1 82 p85 1960 152 1.00 58 1.00 94 1.00
Quintile 2 88 86–90 1947 146 0.92 0.74 1.16 49 0.81 0.55 1.19 96 0.99 0.74 1.31
Quintile 3 93 91–95 2013 183 1.10 0.89 1.37 60 0.94 0.65 1.35 120 1.18 0.90 1.54
Quintile 4 98 96–101 1893 171 1.09 0.87 1.35 54 0.89 0.61 1.29 116 1.20 0.92 1.58
Quintile 5 107 X102 1912 165 1.04 0.83 1.30 60 0.96 0.67 1.38 104 1.08 0.82 1.43
0.35 0.99 0.26
WHR
Quintile 1 0.87 p0.90 1945 161 1.00 58 1.00 96 1.00
Quintile 2 0.91 0.90–0.93 1949 161 1.02 0.82 1.27 53 0.96 0.66 1.39 110 1.04 0.79 1.36
Quintile 3 0.94 0.93–0.96 1958 152 0.97 0.78 1.21 56 1.01 0.70 1.46 107 0.95 0.72 1.25
Quintile 4 0.97 0.96–0.99 1913 187 1.21 0.98 1.50 67 1.23 0.87 1.75 117 1.20 0.92 1.56
Quintile 5 1.02 X0.99 1959 156 1.08 0.87 1.35 47 0.94 0.64 1.39 100 1.13 0.86 1.48
0.17 0.67 0.21
Diabetes?
No n/a n/a 9336 790 1.00 273 1.00 511 1.00
Yes n/a n/a 411 27 0.78 0.53 1.14 8 0.62 0.31 1.26 19 0.87 0.55 1.37
0.20 0.19 0.55
Waist, adjusted for BMI
Quintile 1 n/a n/a 1963 145 1.00 50 1.00 94 1.00
Quintile 2 n/a n/a 1943 165 1.19 0.95 1.49 50 1.10 0.74 1.62 114 1.25 0.95 1.64
Quintile 3 n/a n/a 1963 146 1.01 0.80 1.27 49 1.01 0.68 1.50 97 1.02 0.77 1.35
Quintile 4 n/a n/a 1930 178 1.26 1.01 1.57 65 1.37 0.95 1.98 111 1.20 0.92 1.59
Quintile 5 n/a n/a 1925 183 1.21 0.97 1.51 67 1.28 0.89 1.85 114 1.17 0.89 1.54
0.078 0.083 0.37
WHR, adjusted for BMI
Quintile 1 n/a n/a 1937 169 1.00 57 1.00 112 1.00
Quintile 2 n/a n/a 1968 139 0.89 0.71 1.12 48 0.95 0.65 1.39 90 0.85 0.64 1.12
Quintile 3 n/a n/a 1926 181 1.20 0.97 1.49 65 1.36 0.95 1.95 115 1.12 0.86 1.46
Quintile 4 n/a n/a 1940 166 1.11 0.90 1.38 56 1.18 0.82 1.71 109 1.07 0.82 1.39
Quintile 5 n/a n/a 1945 162 1.15 0.93 1.43 55 1.25 0.86 1.81 104 1.07 0.82 1.40
0.049 0.12 0.24
BMI¼body mass index; WHR¼waist–hip ratio; HR¼hazard ratios. P-values in italics.
aAll P-values are for linear trends (categorical variables), except where noted.
bNumbers
do not always add to 10564 owing to missing values in some categories.
cLinear P-value¼0.92.
dLinear P-value¼0.49.
eLinear P-value¼0.55.
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yTable 2 Age-adjusted and multivariate
a hazard ratios (with lower and upper limits of 95% confidence intervals) for measures of height, obesity, and
diabetes prevalence and cases of prostate cancer occurring before age 65
b
Age-adjusted analysis (n¼8194)
c Multivariate analysis (n¼8103)
d
Non-cases (n¼7992) Incident cases (n¼202)
NN HR Lower Upper HR Lower Upper
Height
Quintile 1 1308 32 1.00 1.00
Quintile 2 1596 31 0.77 0.47 1.27 0.75 0.46 1.23
Quintile 3 1841 50 1.06 0.68 1.65 1.00 0.64 1.58
Quintile 4 1330 22 0.62 0.36 1.07 0.59 0.34 1.02
Quintile 5 1903 67 1.30 0.85 1.98 1.22 0.79 1.89
0.17 0.28
BMI
Underweight 36 3 3.81 1.20 12.08 4.38 1.35 14.17
Normal 3019 78 1.00 1.00
Overweight 3896 94 0.97 0.72 1.31 0.95 0.70 1.29
Obese 1027 27 1.09 0.71 1.69 1.09 0.70 1.71
Non-linear P 0.13
e 0.081
f
BMI
Quintile 1 1640 46 1.00 1.00
Quintile 2 1608 40 0.89 0.58 1.36 0.84 0.55 1.29
Quintile 3 1572 32 0.75 0.48 1.17 0.71 0.45 1.11
Quintile 4 1569 46 1.11 0.74 1.67 1.05 0.69 1.60
Quintile 5 1589 38 0.91 0.59 1.40 0.88 0.56 1.36
0.96 0.93
Body fat %
Quintile 1 1603 36 1.00 1.00
Quintile 2 1597 44 1.20 0.78 1.87 1.20 0.77 1.86
Quintile 3 1607 45 1.27 0.82 1.97 1.28 0.82 1.99
Quintile 4 1558 36 1.08 0.68 1.72 1.05 0.66 1.68
Quintile 5 1576 39 1.19 0.75 1.87 1.20 0.77 1.86
0.65 0.69
Waist
Quintile 1 1626 40 1.00 1.00
Quintile 2 1613 33 0.89 0.56 1.41 0.85 0.53 1.35
Quintile 3 1641 45 1.15 0.75 1.75 1.09 0.71 1.69
Quintile 4 1553 41 1.17 0.76 1.82 1.11 0.71 1.73
Quintile 5 1540 43 1.29 0.84 1.99 1.24 0.79 1.95
0.12 0.19
WHR
Quintile 1 1543 34 1.00 1.00
Quintile 2 1587 30 0.87 0.53 1.42 0.85 0.52 1.40
Quintile 3 1607 39 1.12 0.71 1.78 1.13 0.71 1.80
Quintile 4 1580 52 1.52 0.98 2.34 1.56 1.01 2.43
Quintile 5 1655 47 1.34 0.86 2.09 1.40 0.89 2.21
0.023 0.012
Diabetes?
No 1523 198 1.00 1.00
Yes 6279 4 0.66 0.24 1.77 0.65 0.24 1.75
0.41 0.39
Waist, adjusted for BMI
Quintile 1 1562 35 1.00 1.00
Quintile 2 1626 39 1.05 0.67 1.66 1.05 0.66 1.67
Quintile 3 1625 36 1.04 0.65 1.65 1.03 0.64 1.66
Quintile 4 1609 44 1.28 0.82 2.00 1.29 0.81 2.07
Quintile 5 1551 48 1.57 1.01 2.43 1.59 0.98 2.58
0.025 0.038
WHR, adjusted for BMI
Quintile 1 1472 26 1.00 1.00
Quintile 2 1594 28 0.96 0.56 1.64 0.98 0.57 1.67
Quintile 3 1612 51 1.75 1.09 2.81 1.82 1.13 2.92
Quintile 4 1627 52 1.78 1.11 2.85 1.85 1.15 2.98
Quintile 5 1662 45 1.50 0.93 2.44 1.64 1.00 2.68
0.011 0.004
BMI¼body mass index; WHR¼waist–hip ratio; HR¼hazard ratios. P-values in italics.
aAdjusted for age, height, co-habitation status, socioeconomic status, alcohol habits,
smoking habits, prevalent diabetes, total physical activity, birth country, and total intake of EPA, DHA, red meat, and calcium. Height and prevalent diabetes were further adjusted
for BMI category.
bAll P-values are for linear trends (categorical variables), except where noted.
cNumbers do not always add to 8194 owing to missing values in some categories.
dSome persons excluded from the analyses because of missing values, which also affect the number of cases (n¼200).
eLinear P-value¼0.86.
fLinear P¼0.80.
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a (with lower and upper limits of 95% confidence intervals) for measures of height, obesity, and diabetes
prevalence and total, aggressive, and non-aggressive cases of prostate cancer
b
Incident prostate cancer, entire cohort (n¼10434)
c
All cases (n¼809) Aggressive cases (n¼278) Non-aggressive cases (n¼525)
HR Lower Upper HR Lower Upper HR Lower Upper
Height
Quintile 1 1.00 1.00 1.00
Quintile 2 1.18 0.95 1.47 1.38 0.96 1.98 1.08 0.82 1.43
Quintile 3 1.08 0.86 1.34 1.14 0.79 1.66 1.04 0.79 1.37
Quintile 4 1.04 0.81 1.34 1.01 0.65 1.56 1.08 0.79 1.46
Quintile 5 1.31 1.05 1.64 1.29 0.87 1.91 1.33 1.01 1.76
0.081 0.64 0.055
BMI
Underweight 2.29 1.13 4.63 3.15 1.15 8.62 0.84 0.63 1.11
Normal 1.00 1.00 1.00
Overweight 1.02 0.88 1.19 0.99 0.76 1.29 1.16 0.89 1.50
Obese 1.06 0.84 1.33 1.02 0.69 1.52 1.11 0.85 1.44
Non-linear P 0.15
d 0.16
e 0.65
f
BMI
Quintile 1 1.00 1.00 1.00
Quintile 2 0.94 0.76 1.17 0.83 0.57 1.20 1.01 0.76 1.33
Quintile 3 0.96 0.77 1.20 0.89 0.62 1.29 0.99 0.75 1.31
Quintile 4 0.99 0.80 1.24 0.89 0.61 1.28 1.06 0.81 1.40
Quintile 5 0.90 0.72 1.13 0.83 0.57 1.22 0.94 0.71 1.26
0.58 0.49 0.86
Body fat %
Quintile 1 1.00 1.00 1.00
Quintile 2 1.22 0.98 1.52 1.33 0.94 1.91 1.13 0.85 1.49
Quintile 3 1.03 0.82 1.30 0.99 0.67 1.45 1.05 0.79 1.39
Quintile 4 1.06 0.84 1.32 0.83 0.56 1.23 1.19 0.90 1.56
Quintile 5 1.10 0.87 1.38 1.05 0.71 1.55 1.12 0.84 1.49
0.94 0.35 0.38
Waist
Quintile 1 1.00 1.00 1.00
Quintile 2 0.90 0.71 1.13 0.80 0.55 1.18 0.94 0.70 1.25
Quintile 3 1.05 0.84 1.30 0.93 0.64 1.34 1.10 0.83 1.44
Quintile 4 1.04 0.83 1.29 0.89 0.61 1.30 1.12 0.84 1.47
Quintile 5 1.00 0.80 1.26 0.99 0.68 1.45 1.00 0.75 1.34
0.55 0.84 0.58
WHR
Quintile 1 1.00 1.00 1.00
Quintile 2 0.99 0.79 1.23 0.94 0.65 1.37 1.00 0.76 1.31
Quintile 3 0.96 0.77 1.21 1.03 0.71 1.49 0.93 0.70 1.23
Quintile 4 1.23 0.99 1.52 1.27 0.89 1.82 1.21 0.92 1.58
Quintile 5 1.12 0.89 1.41 0.99 0.66 1.47 1.16 0.88 1.53
0.073 0.46 0.12
Diabetes?
No 1.00 1.00 1.00
Yes 0.76 0.51 1.11 0.61 0.30 1.25 0.84 0.53 1.33
0.15 0.18 0.45
Waist, adjusted for BMI
Quintile 1 1.00 1.00 1.00
Quintile 2 1.17 0.93 1.47 1.11 0.75 1.64 1.21 0.92 1.60
Quintile 3 1.00 0.79 1.27 1.04 0.69 1.55 1.00 0.75 1.33
Quintile 4 1.23 0.98 1.55 1.40 0.95 2.06 1.16 0.87 1.54
Quintile 5 1.17 0.92 1.49 1.29 0.86 1.93 1.11 0.82 1.50
0.18 0.11 0.67
WHR, adjusted for BMI
Quintile 1 1.00 1.00 1.00
Quintile 2 0.89 0.71 1.11 0.96 0.65 1.40 0.84 0.63 1.11
Quintile 3 1.22 0.99 1.51 1.34 0.94 1.93 1.16 0.89 1.50
Quintile 4 1.14 0.92 1.42 1.21 0.83 1.75 1.11 0.85 1.44
Quintile 5 1.22 0.98 1.52 1.27 0.87 1.86 1.17 0.89 1.53
0.012 0.10 0.072
BMI¼body mass index; WHR¼waist–hip ratio; HR¼hazard ratios. P-values are in italics.
aAdjusted for age, height, co-habitation status, socioeconomic status, alcohol habits,
smoking habits, prevalent diabetes, total physical activity, birth country, and total intake of EPA, DHA, red meat, and calcium. Height and prevalent diabetes were further adjusted
for BMI category.
bAll P-values are for linear trends (categorical variables), except where noted.
cSome persons excluded from the analyses because of missing values, which also
affect the number of cases.
dLinear P¼0.95.
eLinear P¼0.72.
fLinear P¼0.95.
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occurring within 2 year of screening, respectively). This was true of
the waist/WHR models, both univariate and multivariate. How-
ever, the association between being underweight according to BMI
classification and increased risk of total PCa was greatly weakened
after removal of cases occurring within the first 2 years or
asymptomatic cases. Apart from these, the sensitivity analyses
yielded no consistent results.
DISCUSSION
This study showed a weak association between tallness and risk of
total PCa, also shown (but not significantly) by aggressive PCa or
PCa in the o65 sub-cohort. The role of height in PCa, if any, is
controversial (Gunnell et al, 2001). A similar finding was reported
in the largest study to date, examining 950000 Norwegian men, in
which the tallest men (X190cm) had an RR of 1.72 (95% CI 1.46–
2.04) compared with the shortest (Engeland et al, 2003). Although
an RR greater than 1.00 for the tallest men has been reported
several times, this was not usually significant at a 0.05 level
(Gunnell et al, 2001). A recent study from the EPIC cohort found
no association between height and risk, neither for aggressive nor
for non-aggressive tumours (Pischon et al, 2008). Furthermore,
height was recently associated with increased PCa mortality
(Giovannucci et al, 2007).
To our knowledge, height in itself has not been regarded as
a causal factor for PCa, but rather associations have been
attributed to genetic, hormonal, and nutritional factors related
to growth until adulthood, both before and after birth (Gunnell
et al, 2001). As there is evidence of a positive association between
body height and socioeconomic class, perhaps reflecting factors
such as a greater abundance of food during growth or lower
incidence of infections, one could imagine socioeconomic class
confounding the association between height and PCa (Batty et al,
2006). In this study, however, this was only marginally affected
by adjustment for socioeconomic index and other potential
confounders.
Few studies have reported associations between waist/WHR and
PCa; a recent meta-analysis judged the evidence to be weak
(MacInnis and English, 2006). In our study, WHR (and, to a
smaller extent, waist) was associated with PCa, particularly before
age 65 and after adjustment for BMI. Detection bias is possible:
persons with higher WHR may be more likely to have other health
problems and therefore visit a doctor, which could increase the
chance of diagnosis. However, the sensitivity analysis showed, if
anything, stronger associations when asymptomatic cases were
excluded (data not shown). Although usually highly correlated
with BMI, there are data to suggest that waist circumference and/or
WHR may predict health problems independently of BMI, as in
diabetes mellitus (Gastaldelli, 2008) and CVD (Yusuf et al, 2005).
Furthermore, there is accumulating evidence for a role of waist
circumference (Visscher et al, 2001; Koster et al, 2008) and WHR
(Lahmann et al, 2002; Price et al, 2006) in predicting mortality
independently of BMI in men. A post hoc analysis of total PCa in
the present cohort shows that the increased PCa risk associated
with large waist circumference seemed to be greatest at low BMI
(data not shown), a finding that was not explained by prevalent
asymptomatic cancer.
It is not clear why the association between WHR and PCa risk
was most pronounced in the o65 sub-cohort, or why height was
not associated with aggressive PCa. Chance findings can never be
entirely ruled out; although the number of factors examined in this
study was limited and well defined, the actual number of statistical
tests was large. On the other hand, our findings might reflect that
unmeasured factors associated with high WHR/waist circum-
ference become relatively less important to PCa development as
age increases. Similarly, height may be a marker of biological
processes leading to less aggressive PCa.
General adiposity was not associated with PCa in this study. The
HR estimates for BF% were slightly different from those for BMI,
but not convincingly so. As the use of BF% as a marker of general
adiposity has recently been criticised (Cole et al, 2008), we
repeated our main analyses with BF% replaced by BF mass
adjusted for lean body mass, but with broadly similar results (data
not shown). One obvious explanation is that there may be no effect
or a very small effect of general adiposity on PCa risk (MacInnis
and English, 2006; Renehan et al, 2008), or that BF% is not
different enough from BMI to capture any differences in this
respect.
Underweight (BMI o18.5) was associated with all categories
of PCa. This may represent weight loss owing to pre-clinical
cancer, particularly since the associations disappeared
after exclusion of cases occurring within the first 2 years after
screening.
Diabetes was not significantly associated with incidence of PCa
in this study. Several studies linking NIDDM and/or insulin
resistance with lower risk of PCa have been published in recent
years (Bonovas et al, 2004; Gong et al, 2006; Stocks et al, 2007). As
noted above, we used self-reported data on diabetes prevalence.
However, because we also defined diabetics by their oral anti-
diabetic drug use, only diabetics without oral therapy (or who
failed to record it) and who did not answer the diabetes item
correctly should be misclassified. This predominantly NIDDM
group may be mixed with type 1 diabetes, because the
questionnaire did not differ between diabetes types. However,
few persons reported age at start of diabetes treatment o36 years
(n¼30, 12% of cases). Finally, it should be noted that our power to
detect an association was rather low, because of the relatively small
number of diabetics.
Many researchers use a Gleason score of 7þ instead of 8þ for
defining more aggressive tumours. Changing our definition of
aggressive to include Gleason 7 meant resulted in another 99 cases
among the aggressive, with unchanged null results and weaker
positive results (data not shown). This could be interpreted as an
effect of diluting the aggressive group of cases by adding a large
number of less malignant tumours.
In this population-based cohort study, we noted positive
associations between risk of PCa and adult height, WHR, and
waist circumference. No other measures of obesity or body size,
or prevalent diabetes were significantly associated with PCa
risk. There were no suggestions of significant interactions
between measures of obesity and degree of aggressiveness of the
tumours.
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